Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 77Lymphoma 62Melanoma 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 42Leukemia 41Lymphoma, Non-Hodgkin 31Burkitt Lymphoma 30Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 26Neuroblastoma 24Lymphoma, Follicular 23Neoplasm Metastasis 21Leukemia, Myeloid, Acute 19Sarcoma 18Lymphoma, Large-Cell, Immunoblastic 18Neoplasms, Plasma Cell 17Lymphoma, Mantle-Cell 17Skin Neoplasms 16Ovarian Neoplasms 14Kidney Neoplasms 14Neoplasms 13Hodgkin Disease 13Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, B-Cell 11Central Nervous System Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Large-Cell, Anaplastic 10

Interventions

Vincristine 3Rituximab 3Prednisone 3Etoposide 3Doxorubicin 3Cyclophosphamide 3varlilumab 1prednylidene 1pomalidomide 1liposomal doxorubicin 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1CT-P10 1Bronchoscopy 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Lymphoma, Primary Effusion × Cyclophosphamide × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡